Gene-ious at Work: Editing the Future for Patients with Sickle Cell Disease By Lucy Williams, PhD student at Cardiff University and runner-up of the BSGCT Scientific Writing Competition. Lucy's research focuses on the development of a precise virus-based cancer therapy that…
After the Window Closes: The New Hope for Neurodevelopmental Disorders By Ouidad Khechaoui, PhD researcher in neurodevelopmental AAV Gene Therapy at the University of Sheffield When the parents of a child with a neurodevelopmental disorder first hear the diagnosis, they…
Biography: I am a clinician in Ear, Nose & Throat surgery in London, and I am currently taking time out of training to undertake a Lewis Spitz Surgeon-Scientist PhD Fellowship in Prof. Jane Sowden’s lab at the Great Ormond Street…
Biography: I am a final year iCASE BBSRC AstraZeneca-funded PhD student at the University of Sheffield in Professor Barbaric’s lab, investigating the mechanisms and consequences of genetically variant human pluripotent stem cells (hPSCs) and their implications for regenerative medicine. Specifically,…
Biography: Grace is a final year BSc Medical Sciences and Engineering student at University College London (UCL) and is completing her thesis at the UCL Centre for Biomaterials in Surgical Reconstruction and Regeneration. Alongside her studies she is serving as…
By Daisy Adamson The COVID-19 pandemic resulted in the rollout of multiple effective vaccines including the Pfizer-BioNTech (BNT162b2) & Moderna (mRNA-1273) messenger RNA (mRNA) -based vaccines, and the Oxford/AstraZeneca (ChAdOx1 nCoV-19) & Janssen (Ad26.COV2.S) adenoviral vectored vaccines (1). The mRNA…
The BSGCT Conference celebrated the path of research that led to today’s ground-breaking treatments. As scientists from around the world descended on London last month to discuss monumental advances in gene and cell therapy research, it is befitting to reflect…
Author: Dr. Rebecca A Lea, University of Sheffield Charcot-Marie-Tooth (CMT) disease is an umbrella term that encompasses a broad range of genetic neurodegenerative diseases, first described by doctors in 1886 [1, 2]. It is characterised by symptoms such as muscle…
Expression of interest: Prosperity partnerships: advanced therapies safety and toxicity Opportunity status: Open Funders: Medical Research Council (MRC) Funding type: Grant Total fund: £10,500,000 Award range: £2,000,000 - £4,000,000 Publication date: 30 August 2024 Opening date: 30 August 2024 9:00am…
This month’s ‘researcher in the spotlight’ is BSGCT mentee, Alexandros Angelopoulos, Northumbria University. Can you tell us about your research or your studies in the field? I am a BSc student at Northumbria University, Newcastle currently undertaking a project investigating…